PMWC 2021 Virtual (part 1)

21st Century Precision Medicine in the Age of COVID-19

January 25-27, 2021, Virtually

 

Day 1 (January 25)

 

    1. PMWC 2021 honoring Dr. Anthony Fauci

Dr. Fauci was appointed Director of NIAID in 1984 and in that position has served as a relentless crusader for some of humanity’s most virulent medical threats. He has advised six Presidents on both HIV/AIDS. He oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat established infectious diseases such HIV/AIDS, respiratory infections, diarrheal diseases, tuberculosis and malaria as well as emerging diseases such as Ebola, Zika and now, COVID-19.

    2. COVID-19 the Disrupter of Biomedical Research and Our Healthcare System

The “value-based healthcare” model has been industry’s theoretical new direction that has never managed to escape from the current legacy system (fee-for-service). The COVID-19 pandemic provides a unique opportunity to disrupt the legacy system, establish value-based strategies, and transform 21st century healthcare through healthcare partners collaboration around a big-data ecosystem.

    3. Tracking COVID-19 with a System Clinical Approach

As the cases of COVID-19 increase, healthcare stakeholders are continuing to search for tools and therapeutics to help stem the tide. Collected data can be mined to surface insights and create value for different industry players – pharma, diagnostic companies, providers, and technology companies. Fireside Chat:

    4. Building a Health Data Platform that Supports COVID-19 Health Care

Understanding disease trajectories and clinical outcomes requires an accelerating, holistic data collection and analysis platform that will deliver new insights into the classification of patients into distinct categories and an understanding the immune response to disease. This session will review the enormous business opportunities that this new ecosystem will provide for each of the partners.

    5. Clinical Trials in the Era of COVID-19

COVID-19 has caused major decrease in the number of new patients entering clinical trials and has required adaptation of many trial procedures. For drug development and R&D to continue, the clinical trials space has to adapt, innovate and explore decentralized trial operations, pragmatic trial designs and virtual options. This panel will explore adaptations to clinical trial design, operations and oversight with a goal of making trials more accessible and efficient.

    6. Health Disparities in the COVID-19 Pandemic Session

COVID-19 is exposing long-standing systemic health and social inequities in our health systems, creating an opportunity for addressing these inequities with the goal of achieving greater equity in the health care of all vulnerable populations. Across the country, deaths due to COVID-19 are disproportionately high among African Americans, LatinX and other minority populations. This panel of scientific researchers, clinicians, community leaders, and public health officials will discuss the reasons for the excess mortality and economic disruption related to COVID-19 among health disparity populations and explore ways to effectively implement interventions to mitigate these outcomes.

COVID-19 Emerging Therapeutics, Vaccine Development & Diagnostics

 

Day 2 (January 26)

 

    1. Deciphering The COVID-19 Immune Response

The current pandemic has highlighted the critical importance of understanding the immune response to SARS-CoV-2. Our immune system has evolved over hundreds of millions of years to protect individuals from millions of different diseases, existing or new ones like the novel coronavirus. Understanding exactly how the immune response responds to SARS-CoV-2 at the individual level and across the population will help us answer some key questions, including: Why do people respond so differently to the virus? How severe is someone’s illness likely to be if they are infected? Once infected, are you immune? And how long does that immunity last? This knowledge is crucial to the development of diagnostics, drugs, vaccines, as well as to redefined and effective health policies necessary to fully reopen society and potentially address future pandemics.

    2. SARS-CoV-2 Vaccines: Updates on Recent Developments and Clinical Results

SARS-CoV-2 vaccines are essential to reducing morbidity and mortality from the novel coronavirus. We will hear from the leading vaccine developers on the status and future prophylactic vaccine development.

    3. Development of New SARS-CoV-2 Therapeutics

The COVID-19 pandemic is driving unprecedented transformation of the global medical research ecosystem through the search for effective new therapeutics that can help ease symptoms and prevent death among COVID-19 patients.

    4. COVID-19 Molecular Testing: Updates on Recent Development & Clinical Results

The COVID-19 pandemic created the need for widespread availability of accurate and efficient diagnostic testing for detection of SARS-CoV-2 and antiviral antibodies in infected individuals. This session will provide updates on various assay techniques and tests for COVID-19 diagnosis.

    5. The Regulatory/FDA Perspective

Modernized regulatory science is being adopted by regulators around the world. The U.S. Food and Drug Administration has released in record time vital new guidance for drug developers that contains critical features for conducting clinical trials and good clinical practice for investigational drugs. The FDA has also launched the Coronavirus Treatment Acceleration Program that provide rapid advice on how best to test and develop promising new therapeutics.

Day 3 (January 27)

 

    1. How COVID-19 Changed Clinical Trial Dynamics and Environment

The COVID-19 pandemic has affected design and conduct of all kinds of clinical trials, not only the specific areas of vaccines and therapeutics directly related to SARS-CoV-2 but also in other major therapeutic areas such as oncology/cancer treatment. This session will provide three different perspectives on this subject: the non-profit perspective that is trying to understand the impact of COVID-19 on recruiting patients for cancer studies, the pharma perspective on performing therapeutic and vaccine trials, and the labs perspective on designing and executing COVID-19 targeted therapeutic and vaccine trials.